Latest Industry Insights

This article walks through the fundamentals of CRISPR screening and its most exciting applications, including unpicking cellular signaling networks, discovering how viruses like COVID-19 infect our cells and finding new drug targets.

This article discusses an innovative biofabrication method that uses a single 3D hydrodynamic flow focusing chip to generate different hydrogel configurations with specific geometries for various biological applications.

Technology Networks recently had the pleasure of speaking with Mark Fidock, vice president for Diagnostic Development, Precision Medicine at AstraZeneca, to find out how the company is “rising to the challenge” of delivering precision medicines for chronic diseases.

Technology Networks recently spoke to Drew Buskirk to learn more about peak variation and why it is so important to measure.

The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.

To understand how machine learning methods and new software capabilities are helping proteomics researchers gain greater depth in their analyses, Technology Networks recently interviewed Tharan Srikumar, product manager in bioinformatics at Bruker Daltonics.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.